Class Action Lawsuit Reminder: Levi & Korsinsky Alert for Unicycive Therapeutics, Inc. (UNCY)

Investors who have a stake in Unicycive Therapeutics, Inc. (UNCY) should take note of a class action lawsuit that could potentially impact their investment. The deadline for involvement is set for October 14, 2025, and those affected should make sure to address any concerns before this date.

The essence of this legal action lies in alleged violations of federal securities laws by Unicycive Therapeutics, Inc. These purported infractions stem from statements made by the company that may have misled investors. If proven true, these inaccuracies could have caused financial harm to those who trusted in the company’s word.

The lawsuit calls attention to Unicycive Therapeutics, Inc.’s troubles involving its drug candidate CY6463. The company faced hurdles in its efforts to secure the U.S. Food and Drug Administration’s (FDA) Investigational New Drug application for this compound. This news resulted in a significant drop in the company’s stock price, leading to financial losses for investors.

Investors who suffered losses due to Unicycive Therapeutics, Inc.’s alleged misrepresentations may be entitled to compensation. This class action lawsuit aims to hold the company accountable for any wrongful actions that may have caused harm to its investors.

Individuals affected by this situation are encouraged to seek legal counsel to understand their rights and options regarding this class action lawsuit. It is essential for investors to act promptly and ensure that they meet the October 14, 2025 deadline for participation in this legal matter.

By staying informed and taking appropriate action, investors can protect their interests and potentially recover losses incurred as a result of Unicycive Therapeutics, Inc.’s alleged misleading statements. This class action lawsuit serves as a reminder of the importance of transparency and accuracy in the financial market, emphasizing the need for accountability when companies fail to uphold these standards.

Investors should remain vigilant and proactive in pursuing the justice and compensation they may be entitled to in cases of securities fraud. By participating in this class action lawsuit, affected individuals can work towards holding Unicycive Therapeutics, Inc. accountable for any wrongful conduct that may have impacted their investments.